APA (7th ed.) Citation

Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, & Kenji Kashiwagi. (2023). A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result. MDPI AG.

Chicago Style (17th ed.) Citation

Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, and Kenji Kashiwagi. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result. MDPI AG, 2023.

MLA (9th ed.) Citation

Wataru Kikushima, et al. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result. MDPI AG, 2023.